Comparison of IBD-related outcomes in patients with obesity treated with GLP-1 receptor agonists versus bariatric surgery [0.03%]
M Housam Nanah,Arjun Chatterjee,Hisham Wehbe et al.
M Housam Nanah et al.
Introduction: The global prevalence of obesity is rising, paralleled by an increase in IBD (inflammatory bowel disease). While studies examining the impact of obesity on IBD have yielded conflicting results, some suggest ...
Building a career in inflammatory bowel disease: strategies to identify and cultivate a niche [0.03%]
炎症性肠病职业发展策略：如何定位及开拓学术领域
Alvin T George,Hilary K Michel,Lisa B Malter
Alvin T George
Intestinal ultrasound in acute severe ulcerative colitis treated with intravenous cyclosporine: case series [0.03%]
静脉注射环孢素治疗急性重度溃疡性结肠炎的肠道超声检查：病例系列报告
Yusuke Miyatani,Joëlle St-Pierre,Jeremy Klein et al.
Yusuke Miyatani et al.
Background: Intestinal ultrasound (IUS) has been studied to assess therapeutic response in patients with acute severe ulcerative colitis (ASUC). However, there is no data on sonographic changes occurring in ASUC receiving...
Paula Prieto Tizzard,Shervin Rabizadeh,Joel R Rosh
Paula Prieto Tizzard
Treatment outcomes of prolonged induction or re-escalation dosing of upadacitinib in patients with inflammatory bowel disease [0.03%]
乌帕替尼长期诱导或剂量递增治疗炎症性肠病患者的疗效结局
Ellen Axenfeld,Vasantham Chaudhary,Joseph W Clinton et al.
Ellen Axenfeld et al.
Background: Proposed treatment algorithms favor the use of upadacitinib in medically refractory Crohn's disease (CD) and ulcerative colitis (UC). There has not yet been data published regarding efficacy of prolonged induc...
Influenza vaccine uptake among patients with inflammatory bowel disease: comparable outcomes between telemedicine and in-person care [0.03%]
炎症性肠病患者流感疫苗接种率：远程医疗与面对面治疗的效果相当
Mazen Almasry,Trevor L Schell,Luke Richard et al.
Mazen Almasry et al.
Background: Patients with inflammatory bowel disease (IBD) receiving immunosuppressive therapies are at increased risk of vaccine-preventable diseases, including influenza. Despite recommendations for annual influenza vac...
Efficacy and safety of ABBV-154 in patients with moderately to severely active Crohn's disease: a phase 2b, randomized, double-blind, placebo-controlled trial [0.03%]
ABBV-154治疗中至重度活动性克罗恩病患者的疗效和安全性：一项2b期、随机、双盲、安慰剂对照试验
Walter Reinisch,Laurent Peyrin-Biroulet,Geert D&#x;Haens et al.
Walter Reinisch et al.
Background: ABBV-154 is an antibody-drug conjugate of adalimumab and a proprietary glucocorticoid receptor modulator. This phase 2b randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of A...
Incidence and prevalence of immune-mediated extraintestinal manifestations in pediatric inflammatory bowel disease: a systematic review and meta-analysis [0.03%]
儿科炎症性肠病中免疫介导的肠外表现的发病率和患病率：系统评价和Meta分析
Ruben J Colman,Sudheer K Vuyyuru,Virginia Solitano et al.
Ruben J Colman et al.
Background: Immune-mediated extraintestinal manifestations (IM-EIMs) are common in pediatric inflammatory bowel disease (pIBD). This systematic review and meta-analysis aimed to summarize the incidence and prevalence of I...
Inflammation significantly alters mucosal transcriptomic signatures in pediatric inflammatory bowel disease [0.03%]
炎症显著改变儿童炎症性肠病的粘膜转录组特征
Alexander Schnell,Xinyi Wei,Jan Bossenz et al.
Alexander Schnell et al.
Objectives and study: Crohn's disease (CD) and ulcerative colitis (UC) share common features of inflammation to a greater extent in children than in adults. However, histopathological scoring systems of mucosal inflammati...
Impact of mirikizumab on patient-reported outcomes and quality of life in patients with Crohn's disease: results from the phase 2 SERENITY study [0.03%]
mirikizumab对克罗恩病患者报告结果和生活质量的影响：来自SERENITY II期研究的结果
Vipul Jairath,Theresa Hunter Gibble,Laurent Peyrin-Biroulet et al.
Vipul Jairath et al.
Background: Mirikizumab is an anti-IL23p19 antibody that has shown efficacy in treating moderately to severely active Crohn's disease in a phase 2 study. We studied mirikizumab's impact on quality of life in these patient...